Top Stories
Giredestrant, now known as Wilserdly, delayed disease progression or death by 62% compared to standard endocrine therapy.
The venture capital firm said the funds will focus on European clinical-stage biopharma and medtech companies.
Besides demonstrating significant improvement in depressive symptoms, the company said its deuterated psilocin analogue also showed rapid onset of action.
The company struck a deal, worth up to $411 million, that centres on TRIMTECH Therapeutics' TRIM21-based targeted protein degradation technology.
The purchase gives Lilly access to the biotech's lead asset, a biparatopic antibody for type 1 and 2 mutant calreticulin (CALR)-driven essential thrombocythemia and myelofibrosis.
Conference News
Company to present its vision for on-premises DNA synthesis at PEGS Europe 2026Key TakeawaysTelesis Bio, a San Diego-based DNA synthesis company, has announced a strategic focus on AI-native drug disc...
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –– Global expert panel established and p...
24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage Full 24-week biomarker and clinical data expected in ...
New findings from the Phase 2 ADDRESS-LC trial identify two distinct biomarker-defined Long COVID endotypes1 associated with different patient responses to bezisterim treatment.Bezisterim treatment wa...
Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentat...



